Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Farnier

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Diabete & Metabolisme|July 1, 1992
Influence of obesity and hypertriglyceridaemia on the low HDL2-cholesterol level and on its relationship with prevalence of atherosclerosis in type 2 diabetesB Verges, J M Brun, G Vaillant, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 12, 1999
Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISAC Desrumaux, A Athias, G Bessède, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1988
Proton nuclear magnetic resonance spectroscopy of plasma lipoproteins in malignancyJ M Nabholtz, A Rossignol, M Farnier, et al.
Atherosclerosis|December 1, 1995
Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemiaC Feillet, M Farnier, L H Monnier, et al.
Annales De Cardiologie Et D'Angeiologie|June 4, 2017
[Familial hypercholesterolemia: A largely underestimated cardiovascular risk]J Ferrières, É Bruckert, S Béliard, et al.
Diabetes & Metabolism|July 6, 2000
Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemiaM Krempf, V Rohmer, M Farnier, et al.
Annales De Biologie Clinique|January 1, 1987
[Reference values of serum transferrin in newborn infants, children and adults]G Plomteux, C Charlier, A Albert, et al.
Annales De Pediatrie|October 1, 1987
[Reference values for serum transferrin in newborn infants and children]G Plomteux, C Charlier, A Albert, et al.
International Journal of Clinical Practice|February 19, 2009
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS studyM Farnier, M Averna, L Missault, et al.
Diabetes, Obesity & Metabolism|February 22, 2011
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trialsL A Leiter, D J Betteridge, M Farnier, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Diabete & Metabolisme|July 1, 1992
Influence of obesity and hypertriglyceridaemia on the low HDL2-cholesterol level and on its relationship with prevalence of atherosclerosis in type 2 diabetesB Verges, J M Brun, G Vaillant, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 12, 1999
Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISAC Desrumaux, A Athias, G Bessède, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1988
Proton nuclear magnetic resonance spectroscopy of plasma lipoproteins in malignancyJ M Nabholtz, A Rossignol, M Farnier, et al.
Atherosclerosis|December 1, 1995
Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemiaC Feillet, M Farnier, L H Monnier, et al.
Annales De Cardiologie Et D'Angeiologie|June 4, 2017
[Familial hypercholesterolemia: A largely underestimated cardiovascular risk]J Ferrières, É Bruckert, S Béliard, et al.
Diabetes & Metabolism|July 6, 2000
Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemiaM Krempf, V Rohmer, M Farnier, et al.
Annales De Biologie Clinique|January 1, 1987
[Reference values of serum transferrin in newborn infants, children and adults]G Plomteux, C Charlier, A Albert, et al.
Annales De Pediatrie|October 1, 1987
[Reference values for serum transferrin in newborn infants and children]G Plomteux, C Charlier, A Albert, et al.
International Journal of Clinical Practice|February 19, 2009
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS studyM Farnier, M Averna, L Missault, et al.
Diabetes, Obesity & Metabolism|February 22, 2011
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trialsL A Leiter, D J Betteridge, M Farnier, et al.
Pageof 5